Infliximab-induced reactivated Langerhan's cell histiocytosis in a patient with ulcerative colitis.
Rodríguez
Henar Núñez
HN
García
Isidro
I
Alba
Alberto
A
Igea
Francisco
F
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab